Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.38 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA4 | P22748 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9651732 | 1.00 | REN (0.39) | RENCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL12642488 | 0.85 | PARP1 (0.43) | RENCHRNB2CHRNA3CHRNA4CHRNB3 | |
| Hydrochloric Acid SCHEMBL18150515 | 0.84 | PARP1 (0.42) | RENCHRNB2CHRNA3CHRNA4CHRNB3 | |
| Hydrochloric Acid SCHEMBL18150513 | 0.84 | PARP1 (0.42) | RENCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL2418102 | 0.83 | REN (0.42) | RENCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL15005734 | 0.83 | REN (0.42) | RENCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL2011996 | 0.83 | REN (0.42) | RENCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL16508868 | 0.82 | CHRNB2 (0.44) | RENCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL28526802 | 0.82 | CHRNB2 (0.40) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL3776345 | 0.81 | REN (0.41) | RENCHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2025-10-07 | — | — | US | disclosed |
| CN-119185569-A | Sustained release delivery system comprising a traceless linker | 诺华股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20230201353-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-20230201353-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-20230201353-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-20200376129-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200376129-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-12-03 | — | — | US | disclosed |
| US-10751417-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2020-08-25 | — | — | US | disclosed |
| US-10751417-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2020-08-25 | — | — | US | disclosed |
| EP-3612233-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | Novartis AG (CH) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018193408-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS AG (CH) | 2018-10-25 | — | — | WO | disclosed |
| EP-3092229-B1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-9458171-B2 | Pyrrolidinyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2015103509-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-5116842-A | Analgesics | GLAXO GROUP LIMITED (GB) | 1992-05-26 | — | — | US | disclosed |
| EP-0398720-A2 | Piperazine derivatives | GLAXO GROUP LIMITED (GB) | 1990-11-22 | — | — | EP | disclosed |
| US-4943578-A | ANALGESICS; CEREBRAL ANTIISCHEMIC AGENTS | GLAXO GROUP LIMITED (GB) | 1990-07-24 | — | — | US | disclosed |
| EP-0343900-A2 | Piperazine compounds | GLAXO GROUP LIMITED (GB) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201353-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | ABCB11, ABCB1, GHRHR | REN 2904/4885CHRNB2 2595/4885CHRNA3 3155/4885 |
| US-20200376129-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | ABCB11, ABCB1, GHRHR | REN 2904/4885CHRNB2 2595/4885CHRNA3 3155/4885 |
| US-10751417-B2 | Sustained release delivery systems comprising traceless linkers | ABCB11, ABCB1, GHRHR | REN 2904/4885CHRNB2 2595/4885CHRNA3 3155/4885 |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | ABCB11, ABCB1, GHRHR | REN 2904/4885CHRNB2 2595/4885CHRNA3 3155/4885 |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | RORC, RORB, RORA | REN 670/4885CHRNB2 2052/4885CHRNA3 1470/4885 |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | RORC, RORB, RORA | REN 1100/4885CHRNB2 1404/4885CHRNA3 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.